Magnesium Depletion in Patients Treated with Therapeutic Hypothermia After Cardiac Arrest by Mazer-Amirshahi, Maryann et al.
Magnesium Depletion in Patients Treated
with Therapeutic Hypothermia After Cardiac Arrest
Maryann Mazer-Amirshahi,1 Sarah M. Perman,2 Anne V. Grossestreuer,3
Robert W. Neumar,4 and David F. Gaieski5
Magnesium (Mg2 + ) depletion can have detrimental effects in postcardiac arrest patients through multiple
potential mechanisms. Therapeutic hypothermia (TH) produces a Mg2+ diuresis, but the effects of postcardiac
arrest TH on serum Mg2+ levels in patients with postcardiac arrest syndrome (PCAS) are yet to be system-
atically quantified. We conducted a retrospective chart review of 119 consecutive comatose PCAS patients
treated with TH between 2005 and 2010 and compared them to 33 matched historic controls (HCs) seen at the
same institution between 2002 and 2005 who were not treated with TH. We abstracted data from the first 96
hours postarrest, including date, time, and value of serum Mg2+ levels and date, time, and amount of Mg2+
repletion, along with outcomes at discharge. The median Mg2+ level of TH patients was 2.0mg/dL [inter-
quartile range (IQR), 1.9–2.2mg/dL] (0.82 mmol/L [IQR, 0.78–0.90 mmol/L]) versus 2.2mg/dL [IQR, 1.9–
2.4mg/dL] (0.90 mmol/L [IQR, 0.82–0.99 mmol/L]) ( p = 0.2) in HCs. In addition, 42.9% (520/1214) of Mg2+
levels in TH patients versus 31.9% (43/135) ( p= 0.014) in HC patients were below 2.0mg/dL [0.82 mmol/L].
The average number of times the Mg2+ level was checked in TH patients was 10.2 (range 1–18) versus 4.1
(range 1–10) in HCs. The TH patients were more likely to receive supplemental Mg2 + than HCs (81.5% [97/
119] vs. 27.3% [9/33] [p< 0.01]). The mean supplemental Mg2+ dose was 1.9 g for TH patients versus 0.5 g for
HC patients. Mortality in patients treated with TH was 53.1% (60/113) versus 78.6% (22/28) ( p = 0.014) in
HCs. Low serum Mg2+ levels with subsequent Mg2+ supplementation were more common in comatose patients
with PCAS treated with TH compared to normothermic HC patients. The effect of untreated hypomagnesemia
on postcardiac arrest outcomes remains to be determined.
Introduction
Magnesium (Mg
2 + ) is a divalent cation that has a
multitude of physiologic effects. Its actions at the cel-
lular level are primarily due to the effects of Mg2+ on calcium
channels, hormone receptor binding sites, and through ade-
nylate cyclase using second messenger systems (Altura, 1994;
Fawcett et al., 1999). Magnesium is a cofactor in more than
300 enzymatic reactions throughout the body (Fawcett et al.,
1999). Magnesium also has well-established effects on the
myocardium and is critical in maintaining normal cardiac
conduction (Iseri, 1990). In the brain, Mg2 + is a natural an-
tagonist at the N-methyl-D-aspartate (NMDA) receptor
channel, and therefore, a potential modulator of neuronal
irritability and excitotoxicity (Kuner and Schoepfer, 1996).
Low serum Mg2 + levels have been associated with cardiac
dysrhythmias (Fawcett et al., 1999), increases in proin-
flammatory cytokines (Weglicki et al., 1992), free radical
injury, shivering in brain-injured patients (Badjatia et al.,
2008; Polderman, 2009), and ultimately, cellular death
(HACA, 2002).
Therapeutic hypothermia (TH) has been demonstrated to
improve neurologic outcomes in comatose patients with
postcardiac arrest syndrome (PCAS) and has become a
standard postresuscitation care in many institutions (HACA,
2002; Young, 2009; Hollenberg et al., 2013). In addition, it
has been postulated that Mg2 + may have neuroprotective
effects during the postcardiac arrest period and low serum
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Mg2 + levels may exacerbate neuronal injury, although this
has not been studied in a controlled randomized manner (Reis
et al., 2008). Despite the clear benefits of TH on neurologic
outcomes, significant adverse effects have been associated
with the use of TH. Electrolyte abnormalities, including hy-
pokalemia, hypophosphatemia, and hypomagnesemia, have
been noted in *20% of patients undergoing TH (Nielsen
et al., 2009).
Although hypomagnesemia has not been definitively
linked with adverse outcomes in the setting of postcardiac
arrest TH, data are currently limited (Polderman, 2004;
Nielsen et al., 2011; Tømte et al., 2011). At the same time,
hypomagnesemia has been associated with adverse effects
and increased mortality in medical patients with critical ill-
ness (Rubeiz et al., 1993; Soliman et al., 2003; Tømte et al.,
2011). The effect of postcardiac arrest TH on Mg2 + levels
has not been specifically investigated. The objective of this
study was to determine if TH after cardiac arrest had a sig-
nificant effect on serum Mg2 + levels and whether clinicians
responded to low Mg2 + levels in TH patients by checking
levels or repleting Mg2 + more frequently.
Materials and Methods
Study design
This study is a retrospective chart review of comatose
patients with PCAS treated with TH between 2005 and 2010
compared to a cohort of comatose historical controls (HCs)
who had a cardiac arrest between 2000 and 2005 and received
standard postarrest care without TH.
Study setting and population
The study was approved by the Institutional Review
Board at the Hospital of the University of Pennsylvania
and conducted at an urban teaching hospital with *58,000
emergency department visits and 100 cardiac arrests an-
nually during the time the study was conducted. Patients
were included if they were q18 years of age, suffered a
cardiac arrest, and had return of spontaneous circulation
(ROSC), but were subsequently comatose and treated with
TH. Coma was defined as a Glasgow Coma Scale (GCS)
< 6 (specifically not following commands). HC patients
would have been eligible for TH had the protocol existed
at the time of their arrest but instead were treated with
standard postresuscitation care, as TH was not the standard
of care at that time.
TH protocol
TH was induced with chilled saline and continued with a
surface cooling system with a target temperature of 33C. Ice
packs were utilized if there was difficulty achieving or
maintaining the target temperature with initial measures. TH
was then maintained for 24 hours. Active rewarming was
performed over at least 8 hours by increasing the temperature
set point by 0.25–0.33C/hour. In addition, patients received
early hemodynamic optimization and standard intensive care
unit measures. Institutional protocol recommends checking
Mg2 + levels every 6 hours during all phases of TH. As part of
the TH protocol, there is a computerized order set that
prompts the clinician to order 2 gMg2 + IV if the serumMg2 +
level is < 1.8 g/dL.
Data collection
Data were obtained for both the TH and HC groups during
the first 96 hours postarrest or until the time of death, which-
ever occurred first. Each patient’s medical record was re-
viewed and data were extracted and entered into a Microsoft
Excel 2007 database (Microsoft Corp, Redmond, WA). Spe-
cific information collected included the date, time, and value
of serum Mg2+ levels, reported in mg/dL and mmol/L, using
the following conversion formula: Mg2+ level (mg/dL)·
0.4114=Mg2+ level (mmol/L). In addition, we collected the
date, time, and amount of Mg2+ repletion. The primary out-
comes were serum Mg2+ levels and the total amount of Mg2+
supplementation that occurred during the study period. Sec-
ondary outcomes included neurologic outcome at hospital
discharge, reported as cerebral performance category (di-
chotomized into good and poor outcomes) and survival to
hospital discharge.
Statistical analysis
All data were analyzed using standard statistical software
(Stata v.12.1, College Station, TX). Continuous data were
analyzed by means with ranges and standard deviations for
parametric data and medians with ranges for nonparametric
data. Comparisons were made using the Student’s t-test and
Mann–Whitney U tests. P-values of < 0.05 were considered
statistically significant. Categorical data were compared us-
ing Fischer’s exact test.
Results
Baseline characteristics and outcomes
One hundred nineteen consecutive comatose PCAS pa-
tients were treated with TH and compared to 33 HCs (Table
1). The mean age of TH patients versus HC patients was
59.8 – 15.3 versus 54.9 – 16.2 years ( p = 0.14). Fifty-seven
percent of TH patients were male compared with 52% for
HCs ( p = 0.62). African-Americans comprised 46% of the
TH group versus 64% in the HCs. Ventricular fibrillation
(VF) or pulseless ventricular tachycardia (VT) was the initial
rhythm in 36% of TH patients and 39% of HCs ( p = 0.72)
Mortality in patients treated with TH was 54% (62/116)
versus 79% (22/28) in HCs ( p = 0.02) (see Table 1 for
complete demographics and outcomes).
Magnesium levels
During the first 96 hours postarrest, patients in the TH group
had Mg2+ levels checked more frequently compared to HC
patients. The average number of times theMg2+ level checked
in TH patients was 10.2– 3.4 versus 4.1– 2.6 times in HCs
( p< 0.01). TH patients had lower median serum Mg2+
levels (2.0mg/dL; interquartile range (IQR), 1.9–2.2mg/dL)
(0.82 mmol/L [IQR, 0.78–0.90 mmol/L]) than HC patients
(2.2mg/dL, IQR, 1.9–2.4mg/dL; p= 0.2) (0.90 mmol/L [IQR,
0.82–0.99mmol/L]). A higher percentage ofMg2+ levelswere
below 2.0mg/dL (0.2 mmol/L) in TH patients than in HC
patients (42.9% [520/1214] vs. 31.9% [43/135]; p= 0.014).
Patients treated with TH were more likely to be given sup-
plemental Mg2+ than HC patients (81.5% [97/119] vs. 27.3%
[9/33]; p< 0.01). The mean Mg2+ dose administered to TH
patients was 1.9– 1.3 versus 0.5– 0.9 g ( p< 0.01) for HC
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patients. Postarrest TH patients given Mg2+ supplementation
received an average total Mg2+ dose of 3.8– 3.2 versus
0.7– 1.5 g ( p< 0.01) for HC patients (Table 2; Fig. 1).
Adverse effects in TH patients
Thirty-eight percent (45/119) of patients had major ad-
verse effects of TH therapy (defined as postarrest fever, skin
breakdown, shivering, and dysrhythmias). The most common
side effect noted was postarrest fever (n = 26), followed by
skin breakdown (n = 12), shivering (n = 8), and dysrhythmias
(n = 5). Patients with adverse effects had significantly lower
mean Mg2 + levels than those without adverse effects (1.98–
0.18mg/dL [0.81 mmol/L] vs. 2.07 – 0.28mg/dL [0.85
mmol/L]; p = 0.015). They also had more Mg2 + repletion
(2.33 – 1.21 vs. 1.27 – 1.23 g; p< 0.001).
Discussion
This preliminary investigation suggests that comatose
PCAS patients undergoing treatment with TH are more likely
to have lower serum Mg2 + levels and receive more Mg2 +
repletion than patients who do not receive TH. These findings
could be the result of TH-associated hypomagnesemia or that
providers at our institution became more vigilant about
monitoring serum Mg2 + levels and repleting Mg2 + com-
pared to the pre-TH era, particularly with an electronic TH
order protocol in place. Ultimately, it is likely that a com-
bination of these factors is at play. Clinicians checked Mg2 +
levels more frequently in a higher percentage of TH patients
and responded to low or low normal levels by repleting Mg2 +
more aggressively in this population. Despite this increased
vigilance, mean serum Mg2 + levels were lower in TH pa-
tients than in HC patients.
Magnesiumwasting is a well-described phenomenon during
TH and results from increased fluid diuresis and temperature-
sensitive changes in Mg2+ ion resorption channels in the as-
cending loop of Henle and the distal tubule of the kidney
(Salem et al., 1995; Weisinger and Bellorin-Font, 1998),
which ultimately promote Mg2+ excretion. It has also been
demonstrated that induction of hypothermia causes the shift of
electrolytes from the extracellular to the intracellular com-
partments (Longstreth et al., 2002). Interestingly, a study by
Tømte et al. (2011) found a greater degree of intracellular
shifting in patients who underwent induction of TH with core-
cooling measures compared to surface cooling; however, the
underlying mechanism of this phenomenon is yet to be elu-
cidated. It is unclear what percentage of changes in Mg2+
levels is due to intracellular shift and what percentage due to
temperature-dependent Mg2+ wasting. In traumatic brain in-
jury (TBI) patients with increased ICP treated with TH, Pol-
derman et al. (2001) demonstrated statistically significantly
increased urine excretion of Mg2+ during cooling, which re-
verted to baseline levels after rewarming (3.7– 1.7 mmol in 6
hours before cooling; 9.5– 4.7 mmol/6 hours during cooling;
3.1– 1.2 mmol in 6 hours after cooling; p< 0.01). The authors
reached very similar conclusions as we did: magnesium ‘‘de-
pletion occurred (in the cooling group) despite the fact that
moderate and, in some cases, substantial doses of (magnesium)
repletion were given to many patients (Polderman et al.,
2001).’’
Table 1. Comparison of Demographics and Outcomes Between Therapeutic Hypothermia
Patients and Historic Controls
Parameter
Therapeutic hypothermia
(n = 119)
Historic controls
(n= 33) p-Value
Mean age (years) (SD) 59.8 – 15.3 54.9 – 16.2 NS
Male sex (%) 68/119 (57%) 14/27 (52%) NS
African-American (%) 55/119 (46%) 17/28 (61%) NS
Caucasian (%) 55/119 (46%) 9/28 (32%) NS
Initial rhythm, VF, or pVT (%) 43/119 (36%) 11/28 (39%) NS
Initial GCS recorded after ROSC (range 3–15) 4 5 NS
Mortality (%) 62/116 (54%) 22/28 (79%) 0.02
Good neurological outcome at hospital discharge
(CPC 1 or 2)
42/53 (79%) 6/6 (100%) NS
CPC, cerebral performance category; GCS, Glasgow Coma Scale; NS, nonsignificant; pVT, pulseless ventricular tachycardia; ROSC,
return of spontaneous circulation; SD, standard deviation; VF, ventricular fibrillation.
Table 2. Comparison of Magnesium Results Between Therapeutic Hypothermia Patients
and Historic Controls
Parameter
Therapeutic hypothermia
(n = 119)
Historic controls
(n = 33) p-Value
Patients who had Mg2 + checked (%) 119 (100%) 33 (100%) 1.00
Mean Mg2 + level, mg/dL (IQR)
[mmol/L (IQR)]
2.0 (1.9–2.2) [0.82 (0.78–0.90)] 2.2 (1.9–2.4) [0.90 (0.82–0.99)] 0.2
Mean No. of serum Mg2 + checks (range) 10.2 (1–18) 4.1 (1–10) < 0.01
No. of Mg2 + values below 2mg/dL
[0.82 mmol/L] (%)
66 (47.5%) 8 (21.6%) 0.005
No. of patients given Mg2 + repletion (%) 97 (81.5%) 9 (27.3%) < 0.01
IQR, interquartile range.
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PCAS is a dynamic critical illness that affects multiple
organ systems, with particular impact on the brain and heart.
It triggers a wide range of pathophysiologic processes, in-
cluding amplified production of inflammatory markers, free
radical generation, mitochondrial and endothelial dysfunc-
tion, and cellular apoptosis (HACA, 2002; Young, 2009;
Hollenberg et al., 2013). Because Mg2 + plays a critical role
in all of these processes, the effects of hypomagnesemia and
the importance of subsequent Mg2 + repletion in PCAS pa-
tients may have significant clinical implications (Weglicki
et al., 1992; Weisinger and Bellorin-Font, 1998; Fawcett
et al., 1999; Iseri, 1990). Patients with PCAS are predisposed
to cardiac dysrhythmias, such as VT and VF, as well as
neuronal dysfunction, all of which may be exacerbated by
hypomagnesemia (Soliman et al., 2003; Polderman, 2004;
Polderman, 2009; Nielsen et al., 2011).
The extent to which hypomagnesemia affects clinical
outcomes in patients undergoing TH postcardiac arrest re-
mains unclear. We found significantly lower Mg2 + levels in
patients with adverse effects of TH versus those without
adverse effects of TH. A study by Nielsen et al. (2011) did not
find an association between hypomagnesemia and increased
mortality in PCAS patients treated with TH. In an attempt to
further explore this question, Longstreth et al. conducted a
randomized controlled trial of infusion of Mg2 + , diazepam,
or both, immediately after ROSC to comatose survivors of
cardiac arrest. After controlling for potential confounders,
there was no difference in outcomes between the treatment
arms (Longstreth et al., 2002). The Duke Internal Medicine
Housestaff performed a randomized trial of magnesium in-
fusion during cardiac arrest for patients with in-hospital
cardiac arrest at Duke Hospital. Seventy-six patients ran-
domized to receive a bolus of 2 g of Mg2 + during arrest
followed by 8 g of Mg2 + over the next 24 hours were com-
pared to 80 patients who received placebo. The investigators
found no differences between the groups in the percentages
who achieved ROSC, survival to hospital discharge, or good
neurological outcomes (Thel et al., 1997). However, these
approaches of intra-arrest, immediate post-ROSC, or pro-
phylactic infusion of Mg2 + are significantly different from
the measurement and maintenance of normal Mg2 + levels
over the 96-hour postarrest period. Ultimately, the true
clinical impact of TH-induced hypomagnesemia as well as
the optimal management strategy is yet to be determined.
Our results suggest that hypomagnesemia occurs in a
significant percentage of PCAS patients undergoing TH and
this finding may have relevance when designing and im-
plementing the optimal management strategy and institu-
tional TH protocols. This is particularly important because of
the critically ill nature of the patients involved. Institutional
TH protocols should be designed not only to prompt pro-
viders to frequently monitor Mg2 + levels but also to provide
adequate Mg2 + repletion. Based on prior data, patients who
undergo THwith core-coolingmeasures may be at higher risk
for hypomagnesemia and may require more vigilant moni-
toring and intervention (Tømte et al., 2011). It is also im-
portant to keep in mind that hypomagnesemia may persist
despite aggressive repletion. For example, as noted previ-
ously, Polderman et al. (2001) documented a similar Mg2 +
diuresis in patients with TBI treated with TH, where the urine
output increased and serum Mg2 + levels decreased despite
significant Mg2 + repletion. In a subsequent review of the
mechanism of action, physiological effects, and complica-
tions associated with TH, Polderman suggested that Mg2 +
levels ‘‘should be kept in the high normal range during and
after hypothermia treatment (Polderman, 2009). Extrapola-
tion of these findings to patients treated with postcardiac
arrest TH is difficult because a significant percentage of the
TH-TBI patients were also treated with mannitol, a potent
osmotic agent, which was not used in our patient population.
Our study raises important questions regarding Mg2 +
monitoring and repletion in the postarrest state, which rep-
resents an opportunity for future research. Should Mg2 +
levels be corrected only when they fall below the lower ref-
erence range of normal or should prophylactic supplemen-
tation be instituted? Should Mg2 + levels be aggressively
maintained in a normal range to treat and prevent shivering
and other side effects of cooling? Or should Mg2 + be infused
until supratherapeutic levels are achieved to optimize organ
protection? These questions remain unanswered. It is also
unclear to what extent TH-induced hypomagnesemia affects
clinical outcomes. Finally, systematic studies should be
performed to evaluate whether a synergistic neuroprotective
effect of Mg2 + supplementation and TH exists. Because of
the critically ill nature of PCAS patients undergoing TH and
the lack of data regarding the outcomes associated with as-
sociated hypomagnesemia, we recommend that clinicians
treating these patients should monitor serum Mg2 + levels on
FIG. 1. Magnesium values
over time for TH and HC
patients. HC, historic con-
trols; TH, therapeutic hypo-
thermia.
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a frequent set schedule and aggressively replete Mg2 + to
maintain levels in the midrange of normal. In addition, efforts
should be made to educate physicians and other healthcare
providers whomanage TH patients regarding the potential for
hypomagnesemia.
Limitations
Our study is limited by its small sample size and retro-
spective design. Furthermore, the number of patients in the HC
group is approximately half of that in the hypothermia group.
We speculate that this occurred for a number of reasons. (1)
Inherent limitations in historic chart reviews, including in-
sufficient documentation of neurologic status to determine
coma postarrest; (2) changes in the Philadelphia Emergency
Medical Services leading to increased numbers of arrests
brought to our hospitals; and (3) referrals to our center as we
established ourselves as a cardiac arrest center. In addition,
Mg2+ levels were checked less frequently in historical control
patients and there was no specific protocol for repletion in
those patients. Provider knowledge of TH-induced hypomag-
nesemia was not evaluated. We did not explore the adverse
events related to hypomagnesemia, and this study was not
designed to assess a clinical benefit frommaintaining a normal
Mg2+ level when treating PCAS patients with TH.
Conclusions
Targeted temperature management is now considered the
standard of care to optimize neurological recovery in coma-
tose PCAS patients. Our results suggest that TH induces a
significant Mg2+ diuresis and intracellular shifting, requiring
frequent monitoring of serumMg2+ levels and adequateMg2+
repletion, with a goal of keeping serum levels within the
normal range. Given its possible neuroprotective effect, stan-
dardized intervals for checking and repleting Mg2+ may im-
prove the care of comatose PCAS patients undergoing
treatment with TH. Additional studies should be performed to
investigate the clinical effects of TH-induced hypomagnese-
mia and whether there is a relationship between Mg2+ levels
and TH on outcomes in comatose survivors of cardiac arrest.
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